1. Palliative therapy for osteosarcoma
- Author
-
Pietro Ruggieri, Nikolin Ali, Gaetano Bacci, Costantino Errani, Marco Alberghini, Alessandra Longhi, Mario Mercuri, Angelo Toscano, Piero Picci, Alessio Biazzo, Giuseppe Rossi, Eugenio Rimondi, Errani C, Longhi A, Rossi G, Rimondi E, Biazzo A, Toscano A, Alì N, Ruggieri P, Alberghini M, Picci P, Bacci G, and Mercuri M.
- Subjects
Male ,Oncology ,medicine.medical_specialty ,Lung Neoplasms ,Palliative care ,medicine.medical_treatment ,Antineoplastic Agents ,Bone Neoplasms ,embolization ,bone tumor ,chemotherapy ,Disease-Free Survival ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Pharmacology (medical) ,Embolization ,Survival rate ,Neoadjuvant therapy ,bone tumors ,Osteosarcoma ,business.industry ,Standard treatment ,Palliative Care ,Limb Salvage ,medicine.disease ,Neoadjuvant Therapy ,Radiation therapy ,Unresectable Osteosarcoma ,osteosarcoma ,Disease Progression ,Female ,Neoplasm Recurrence, Local ,business - Abstract
Despite advances in diagnostic imaging, the evolution of neoadjuvant chemotherapy and the refinements in limb-salvage surgery, the progression-free survival rate remains poor for patients with metastatic, recurrent or unresectable osteosarcoma. Different therapeutic strategies for these subgroups of patients have been employed to control disease and prolong survival. Treatment options are limited and controversial, including systemic and localized therapies. Surgical resection, whenever feasible, is still the standard treatment in advanced osteosarcoma. The role of chemotherapy is unclear while the use of radiotherapy, embolization and thermal ablation is increasing. New therapeutic experimental approaches and novel target therapies are needed to improve the outcome of these subgroups of patients.
- Published
- 2011